{"id":"NCT03168334","sponsor":"Bausch Health Americas, Inc.","briefTitle":"A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (302)","officialTitle":"A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2 Arm, Parallel Group Study Comparing the Safety and Efficacy of IDP-123 Lotion and IDP-123 Vehicle Lotion in the Treatment of Acne Vulgaris","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-07-11","primaryCompletion":"2018-07-24","completion":"2018-07-24","firstPosted":"2017-05-30","resultsPosted":"2021-04-01","lastUpdate":"2021-04-01"},"enrollment":801,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Acne Vulgaris"],"interventions":[{"type":"DRUG","name":"IDP-123 Lotion","otherNames":["IDP-123"]},{"type":"DRUG","name":"IDP-123 Vehicle Lotion","otherNames":["Vehicle"]}],"arms":[{"label":"IDP-123 Lotion","type":"EXPERIMENTAL"},{"label":"IDP-123 Vehicle Lotion","type":"PLACEBO_COMPARATOR"}],"summary":"This is a multi-center, randomized, double-blind, vehicle-controlled, 12-week study designed to assess the safety, efficacy, and tolerability of IDP-123 Lotion in comparison with IDP-123 Vehicle Lotion.","primaryOutcome":{"measure":"Absolute Change in Mean Lesion Counts at Week 12","timeFrame":"Baseline to Week 12","effectByArm":[{"arm":"IDP-123 Lotion","deltaMin":-24.6,"sd":15.33},{"arm":"Vehicle Lotion","deltaMin":-16.6,"sd":15.48}],"pValues":[]},"eligibility":{"minAge":"9 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":45,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":387},"commonTop":["Viral Upper Respiratory Tract Infection","Application Site Pain"]}}